SCCM Resource Library-FGF21 Therapy Attenuates Ischemia-Mediated Downregulation of Neuroprotective RBM3 in Newborn Mice

FGF21 Therapy Attenuates Ischemia-Mediated Downregulation of Neuroprotective RBM3 in Newborn Mice

Video Transcription

Video Summary

The video discusses the use of FGF21 therapy in treating neonatal hypoxic ischemic brain injury. Therapeutic hypothermia is commonly used for this condition, but its effectiveness in children and adults after cardiac arrest is uncertain. The study focused on cold stress hormone FGF21, which has been found to be neuroprotective. The researchers used the Rice-Vinucci model to induce brain injury in mice and characterized the model before administering FGF21 therapy. They found that FGF21 supplementation decreased markers of cellular apoptosis and necrosis, protected the neuroprotective cold shock protein RBM3, and increased another cold shock protein called cold-inducible RNA binding protein.

Asset Subtitle

Neuroscience, Research, 2023

Asset Caption

Type: star research | Star Research Presentations: Neuroscience, Pediatrics (SessionID 30006)

Meta Tag

Content Type Presentation

Knowledge Area Neuroscience

Knowledge Area Research

Membership Level Professional

Membership Level Select

Tag Cerebral Ischemia

Tag Outcomes Research

Year 2023

Keywords

FGF21 therapy

neonatal hypoxic ischemic brain injury

therapeutic hypothermia

cardiac arrest

cold stress hormone

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.